Immunotherapy Coverage from Every Angle
Advertisement
Advertisement

Available Clinical Trials

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent NSCLC Following Immunotherapy
A Study to Learn About the Effects of the Combination of Elranatamab
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I NSCLC With Primary Tumors Between 1–4 cm
VG161 in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
A Study of Intratumoral Injection of Dendritic Cells After High-Dose Conformal External-Beam Radiotherapy in Patients With Unresectable Liver Cancer
A Phase III Study Assessing the Addition of Atezolizumab Immunotherapy to the Usual Radiation Treatment for Patients With Early NSCLC
A Phase I/II Study of Relatlimab in Combination With Nivolumab and Bevacizumab for People With Advanced Liver Cancer
A Phase III Study of Durvalumab, Tremelimumab, and Transarterial Chemoembolization (TACE) Given With or Without Lenvatinib Compared to TACE Alone in People With Localized Liver Cancer
Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Nonsquamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in NSCLC
Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study of Multiple Immunotherapy-Based Treatment Combinations in Advanced Liver Cancers
Is Chemotherapy, Bevazicumab, and Atezolizumab Better Than Chemotherapy Alone in Patients With Advanced Liver Cancer?
Atezolizumab in Combination With a Multikinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
A Randomized, Open-label, Phase II Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-Naive Subjects With Advanced or Metastatic PD-L1 High NSCLC Without Actionable Genomic Alterations
A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab vs Standard of Care in Stage IV or Recurrent NSCLC
Copyright © 2024 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.